$0.42
(3.32%)
Create an alert
Stocks and Shares ISAClimb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics that address significant unmet need for patients living with immune-mediated diseases. Its lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells. By targeting CD19, budoprutug has the potential to provide reductions in B cells and pathogenic autoantibodies. The Company is developing budoprutug for the treatment of primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). The Company is in Phase II clinical trial of budoprutug for pMN, Phase Ib/IIa clinical trial for ITP, and Phase Ib clinical trial of budoprutug for SLE. The Company is also developing CLYM116, an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody being developed for the treatment of immunoglobulin A nephropathy.
Company Information
About this company
Key people
Douglas E. Williams
Independent Chairman of the Board
Aoife M. Brennan
President, Chief Executive Officer, Director
Susan Altschuller
Chief Financial Officer, Principal Accounting Officer, Treasurer
Perrin Wilson
Chief Business Officer
Andrew David Levin
Director
Stephen Thomas
Director
Alexander Cumbo
Independent Director
Kimberlee Cobleigh Drapkin
Independent Director
Click to see more
Key facts
- Shares in issue57.26m
- EPICCLYM
- ISINUS28658R1068
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$730.10m
- Employees28
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.